BIM 23190

Drug Profile

BIM 23190

Alternative Names: BIM23190

Latest Information Update: 04 May 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biomeasure Inc; Ipsen
  • Developer Ipsen
  • Class Antineoplastics; Oligopeptides; Piperazines
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic retinopathy

Most Recent Events

  • 23 Jul 2003 BIM 23190 has been exclusively licensed to Teijin in Japan
  • 03 Jun 2003 Beaufour-Ipsen is now called Ipsen
  • 25 Sep 2002 Phase-II clinical trials in Diabetic retinopathy in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top